33 results about "Cirrhosis" patented technology

The invention discloses a portable ascites aspirator for cirrhosis, and relates to the technical field of ascites aspirates.The portable ascites aspirator for cirrhosis comprises a shell, a connecting pipe and a top plate; the device further comprises a suction assembly. The suction assembly comprises a water storage bag, a cleaning disc, a spray head, a guide rod, a driving motor, a cleaning pump, a connecting pipe, a suction bottle and a moving rod; the suction bottle is fixed in the shell and used for storing pumped liquid, the water storage bag is located at the top of the suction bottle, liquid used for cleaning the suction bottle is stored in the water storage bag, and the cleaning pump is fixed in the water storage bag; the nozzle is fixed at the edge of the cleaning disc, the cleaning disc is a hollow circular disc and is connected to the guide rod in a sliding manner, the guide rod is fixed in the suction bottle, and the cleaning disc is spirally connected to the moving rod; the water storage bag is an annular bag, and the connecting pipe penetrates through a round hole in the center of the water storage bag and extends into the suction bottle. The suction device can be cleaned in time, cross contamination is avoided, the suction device is cleaned under the condition that the suction device is not disassembled, and then the service life of the suction device is prolonged.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

Provided herein is a method of diagnosing or prognosing advanced liver fibrosis or liver cirrhosis in a patient. The method is accomplished by determining a score based on the circulating levels in serum of two markers.

The present invention relates to the technical field of liver-protecting formula compositions, and in particular, to a liver-protecting milk thistle formula composition, and a preparation method thereof. Technical problems: the liver-protecting milk thistle formula composition, and a preparation method thereof are intended to solve the technical problems that most of existing liver-protecting compositions in the prior art are designed for the general liver protection needs of the general population and cannot specifically treat liver damage caused by excessive alcohol intake and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia. Technical solution: a liver-protecting milk thistle formula composition, including the following components: silymarin, puerarin, artichoke extract, glutathione, dandelion extract, and GABA. The liver-protecting formula composition has a good therapeutic effect on liver damage caused by excessive alcohol intake, and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia.

The invention relates to an automatic preparation method and device of a medicament for treating liver cirrhosis. A traditional Chinese medicine decoction is prepared from the following raw materials in parts by weight: 10 parts of radix astragali, 5 parts of radix notoginseng, 15 parts of radix salviae miltiorrhizae, 10 parts of rhizoma atractylodis macrocephalae stir-fried with bran, 10 parts of poria cocos, 10 parts of fructus aurantii stir-fried with bran, 15 parts of vinegar turtle shell, 5 parts of vinegar schisandra chinensis, 15 parts of vinegar tortoise shell, 10 parts of peach kernel, 10 parts of radix curcumae, 15 parts of Chinese lobelia and 20 parts of phyllanthus urinaria. An automatic preparation device of the liver cirrhosis treatment medicament is applied, and the method comprises the following steps: S1, filling; s2, performing soaking; s3, decocting first; s4, group decoction; s5, later operation is carried out; s6, squeezing; a standardized decoction process aiming at a specific liver cirrhosis treatment prescription can be executed in a single container through exquisite mechanical linkage and automatic control in a whole process without manual intervention, and a specific traditional Chinese medicine formula (astragalus membranaceus, vinegar turtle shell and the like) is deeply combined with an automatic operation process of the device, so that a set of optimized preparation process is formed.

This AMPK activation composition comprises teadenol A.

The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.

A system for managing liver disease, the system comprising an electronic medical record system comprising a plurality of patient records. The system comprising a patient management platform configured to access the electronic medical record (EMR) system to retrieve medical records of one or more patients, analyze the medical records to selectively identify data related to a liver condition, interface with one or more data analysis platforms configured to receive and analyze the data related to a liver condition. Based on analysis by the patient management interface and / or the data analysis platforms, a display is generated comprising: specific liver-related patient attributes and conditions, and at least one of: a liver health prognosis or a recommended treatment for addressing the liver condition corresponding to the one or more patients. The liver condition can comprise one or more of: cancer, cirrhosis, liver failure, fatty liver disease, steatosis, ischemia, and / or hepatitis.

The present invention relates to 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

Described herein are methods and compositions related to inhibiting bile salt hydrolase (BSH) and uses thereof. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), gastrointestinal disease (e.g., a gastrointestinal infection; inflammatory bowel disease (IBD); appendicitis; Crohn's disease (CD); ulcerative colitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetes; hepatitis; liver diseases (e.g., Non-alcoholic Fatty Liver Disease (NAFLD); non-alcoholic steatohepatitis (NASH); hepatitis A; hepatitis B; hepatitis C; autoimmune hepatitis; and cirrhosis of the liver) gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcer; infectious colitis; irritable bowel syndrome; leaky gut; and cancer), cancer (e.g., cancer of the digestive system, liver cancer), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVIII).

The present invention relates to the medical use of specific long-acting glucagon analogues having dual GLP-1 / glucagon receptor agonist activity in the prevention and / or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), non- alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-associated liver fibrosis and / or cirrhosis.

Disclosed are peptides that are useful as agonists of GPR56. Also disclosed are compositions comprising at least two synthetic or recombinant peptides, each of the peptides comprising a sequence selected from LLSSR, GYYCG, and NQGCKL, or a sequence that has a sequence identity of at least 60% thereto, wherein when a peptide comprises sequence a) or b) the peptide has a length of from 5-25 amino acids and wherein when a peptide comprises sequence c) the peptide has a length of from 6-26 amino acids. The compositions are useful for treating diseases or conditions such as vascular dysfunction, cardiovascular disease, impaired pancreatic -cell function, type II diabetes, impaired glucose tolerance, liver dysfunction, cirrhosis, liver cancer, depression, Alzheimer's disease, retinopathy and Attention deficit hyperactivity disorder.

Part of this invention provides novel small molecule PHD inhibitors having structures according to formula (I) and its derivatives: or pharmaceutically acceptable salts thereof. The compounds provided herein may be used to treat the following diseases: including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory diseases (e.g., respiratory infections, acute respiratory distress syndrome), liver diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute kidney injury and chronic kidney disease), inflammatory bowel disease (IBD), ischemic-reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).

The application discloses use of Acorus gramineus or an extract thereof in preparation of a medicine for treating and / or preventing diseases caused by liver injury and use in preparation of a medicine for treating and / or preventing diseases and / or conditions related to diseases caused by liver injury. The diseases caused by liver injury can be acute liver injury, chronic liver injury, liver fibrosis, liver cirrhosis, liver cancer and the like. The Acorus gramineus or the extract thereof has a liver protection effect, and proves to have a protective effect on the diseases caused by liver injury through liver function indexes and liver pathological staining, and is expected to become a new therapeutic drug for liver injury diseases.

The application discloses a kind of Miao medicine composition for treating liver fibrosis and cirrhosis ascites and its preparation method and application, belong to traditional Chinese medicine and national medical technology field.The composition is made of specific weight ratio of chases yellow grass, pearl grass, white flower snake tongue grass, bupleurum, vinegar baked turtle shell, Miao medicine soft liver grass (dried whole grass of gold star fern), catpaw grass, rhizoma sparganii, zedoary, peach kernel, rehmannia, astragalus, atractylodes, angelica, salvia miltiorrhiza, calcined oyster, big belly skin, poria cocos, curcuma, prepared rehmannia, white peony root, chuanxiong.The application provides pill, granule, capsule and the like controllable preparation process, and the product quality is stable, and safety is high.Experiment and clinic confirm that the composition can significantly reverse liver fibrosis, quickly subsides cirrhosis ascites and reduces recurrence rate, simultaneously improves liver function, liver elasticity, serum albumin and blood coagulation function, is suitable for long-term treatment of liver fibrosis and cirrhosis ascites, and has good industrial application prospect.

This disclosure relates to compounds of formula (I-1) or (I-2): This relates to TIFF2026513962000575.tif74102. The compounds of this disclosure can inhibit the activity of tyrosine kinase 2 (TYK2), for example, in inflammation, autoimmune diseases, neuroinflammation, arthritis, rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, lupus nephritis, arthritis, osteoarthritis, gouty arthritis, pain, fever, pulmonary sarcoidosis, silicosis, cardiovascular disease, atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury, cardiomyopathy, stroke, ischemia, reperfusion injury, cerebral edema, head trauma, neurodegeneration, liver disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, nephritis, retina It is useful in treating diseases or disorders such as inflammation, retinopathy, macular degeneration, glaucoma, diabetes (type 1 and type 2), diabetic neuropathy, viral and bacterial infections, myalgia, endotoxin shock, toxic shock syndrome, autoimmune diseases, osteoporosis, multiple sclerosis, endometriosis, menstrual pain, vaginitis, candidiasis, cancer, fibrosis, obesity, muscular dystrophy, polymyositis, dermatomyositis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, vitiligo, alopecia, Alzheimer's disease, skin flushing, eczema, psoriasis, atopic dermatitis, and sunburn. This disclosure further provides a method for preparing the compound.

The invention relates to the technical field of biological molecular diagnosis of hepatitis B related diseases, and particularly discloses a group of HBV related liver injury diagnostic markers and application thereof. According to the serum exosomes tRF-Val-TAC, tRF-Lys-CTT and tRF-Lys-TTT provided by the invention, the tRFs marker is tRFs combined detection of any one or combination of the sequences, and has the index advantages of high AUC value, high sensitivity and strong specificity; the method can solve the problem of difficulty in early and accurate diagnosis of hepatitis B-related chronic plus acute liver failure (HBV-ACLF) caused by pure dependence on traditional biochemical and blood coagulation indexes, and can meet various diagnosis requirements of ACLF, chronic hepatitis B and cirrhosis.

This invention relates to the use of a recombinant protein ANG in the preparation of a medicament for treating metabolic dysfunction-related steatohepatitis. Specifically, this invention provides the use of the angiopoietin ANG gene, or its protein, or its promoter, for the preparation of medicaments, compositions, or formulations for the prevention, improvement, and / or treatment of liver-related diseases. It is particularly effective in treating metabolic dysfunction-related steatohepatitis, liver fibrosis, and cirrhosis.

The present disclosure relates, in general, to compositions comprising phosphatidylcholine and phosphatidylcholine derivatives, e.g., DLPC (1, 2-dilauroyl-sn-glycero-3-phosphocholine) or DPPC, for the treatment of fibrosis, including liver fibrosis and associated conditions such as fatty liver disease, non-alcoholic steatohepatitis (NASH) and cirrhosis, or lung fibrosis and conditions associated with lung fibrosis.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof:or a pharmaceutically acceptable salt thereof.  The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g., respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI). 

This invention provides a traditional Chinese medicine composition with hepatoprotective and alcohol-relieving effects, made from the following raw materials in parts by weight: 1-5 parts rose petals, 1-5 parts chrysanthemum, 1-5 parts Japanese raisin tree fruit, 1-5 parts paper mulberry fruit, and 1-5 parts kudzu root. The traditional Chinese medicine composition of this invention can be prepared into decoctions, granules, powders, capsules, tablets, mixtures, or oral liquids using conventional pharmaceutical methods. The formulation of the traditional Chinese medicine composition of this invention is based on traditional Chinese medicine theory combined with modern medical research findings, and has hepatoprotective and alcohol-relieving effects. Experimental studies have shown that this composition has good preventive and therapeutic effects on alcoholic liver damage and cirrhosis.

The present invention relates to the use of Eraffibularox for the treatment of primary biliary cholangitis (PBC) and cirrhosis in a subject suffering from PBC, preferably in a subject having a Child-Pugh score A or a Child-Pugh score B. The present invention also relates to the use of Eraffibularox for the treatment of PBC in a subject having a Child-Pugh score A or a Child-Pugh score B.

The present invention relates to a pharmaceutical compound or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of the following conditions, wherein the pharmaceutical compound or a pharmaceutically acceptable salt thereof is characterized in that it simultaneously inhibits autotaxin (ATX) and agonizes PPARγ, and has a chemical formula selected from the group consisting of formulas (A), (B), (C), (D), (E), (F), (G), and (H): a) fibroproliferative diseases, in particular interstitial lung diseases (ILD) and / or liver diseases such as all types of hepatitis and / or non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH) and / or cirrhosis, where the ILD is a primary disease, preferably idiopathic pulmonary fibrosis and / or sarcoidosis and / or interstitial pneumonia, or where the ILD is associated with an autoimmune and / or inflammatory and / or metabolic disease, preferably rheumatoid arthritis-ILD ​​and / or scleroderma-ILD and / or myositis-ILD ​​and / or diabetes-ILD ​​and / or cardiovascular disease-ILD combination, and / or b) an inflammatory and / or autoimmune disease, preferably rheumatoid arthritis and / or scleroderma, and / or c) cancer, in particular lung cancer and / or hepatocellular carcinoma and / or pancreatic cancer and / or glioblastoma and / or neuroblastoma, and / or d) metabolic diseases, in particular type 1 diabetes and / or type 2 diabetes and / or obesity [Formula 1] TIFF2026503883000014.tif94126

The invention relates to compounds of formula (I), wherein R1 is selected from the group consisting of H, C1-3-alkyl, C1-3-haloalkyl, -CH2-CO-NH2, -CH2-CO-NHCH3 and -CH2-CO-N(CH3)2 R2 is selected from the group consisting of H, halogen, (C1-3)-alkyl and halo-(C1-3)-alkyl, R3 is selected from the group consisting of C1-3-alkyl, five- or six-membered heterocyclic ring with 1 to 3 heteroatoms selected from N, O, S or SO2 and a five- or six-membered carbocyclic ring, wherein R3 is substituted by one or two substituents R8 which are each independently selected from the group consisting of H, C1-3-alkyl, -CO-O-(C1-4-alkyl), halogen, CN, OH, O-C1-3-methyl and -CO-(C1-3-alkyl), wherein each V, U, Q and T are independently from each other selected from C or N, wherein R4 is selected from the group consisting of H, halogen, -methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, wherein R5 is selected from H, halogen, methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, wherein R6 is selected from H, halogen, methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, wherein R7 is selected from H, halogen, methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, and pharmaceutical acceptable salts thereof, for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonopathies, metabolic dysfunction associated Steatohepatitis (MASH), interstitial lung disease (ILD), decompensated liver cirrhosis and idiopathic pulmonary fibrosis (IPF).

[Problem] The purpose of the present invention is to provide a composition capable of inhibiting diseases other than oral diseases. [Solution] The present invention is a growth inhibitor for Fusobacterium bacteria, and contains cyclodextran and / or a derivative thereof. The inhibitory effect of Fusobacterium bacteria contributes to the treatment and prevention of ulcerative colitis, cirrhosis, obesity, colon cancer, esophageal cancer, oral cancer, breast cancer, ovarian cancer, cervical cancer, oral squamous cell carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, premature birth, endometriosis, and the like.

Provided herein are in silico methods of modeling hepatic inflammation, fibrosis / cirrhosis, and cancer. The models are computer-implemented agent-based models and are useful in determining patient prognoses in hepatic conditions, including viral infections, damage, inflammation, and cancer. The modeling system also is useful in modeling the effects of active agents on normal hepatic tissue or hepatic tissue perturbed by inflammation, infection, damage, fibrosis / cirrhosis, and cancer.

Provided herein is a method of diagnosing or prognosing advanced liver fibrosis or liver cirrhosis in a patient. The method is accomplished by determining a score based on the circulating levels in serum of three markers.

The present application belongs to the technical field of traditional Chinese medicine, and mainly relates to a traditional Chinese medicine composition and a preparation method thereof, in particular to a traditional Chinese medicine composition for treating liver diseases and a preparation method and application thereof. The present application is prepared by using whiteflower snake tongue grass, schisandra chinensis, radix pseudostellariae, ganoderma lucidum and liquorice through segmented fermentation of lactobacillus rhamnosus CICC-6133 and bifidobacterium breve CICC-6182 to improve performance, and then through water extraction, concentration and drying, and has an improvement effect on alcoholic fatty liver, hepatitis B, gastric mucosa damage, cirrhosis ascites and advanced liver cancer.